Adjuvant CMF (cyclophosphamide, methotrexate, fluorouracil) in breast cancer. Is it cost-effective?

被引：0
|
作者：
Norum, J [1 ]
机构：
[1] Univ Tromso Hosp, Dept Oncol, N-9012 Tromso, Norway
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)81319-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
899
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [31] ESTROGEN-RECEPTORS AND RESPONSE TO CYCLOPHOSPHAMIDE, METHOTREXATE AND 5-FLUOROURACIL (CMF) IN ADVANCED BREAST-CANCER
    CHANG, JC
    HILL, GW
    WERGORSKI, G
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 411 - 411
  • [32] THE EFFECT OF POSTOPERATIVE AND PRIMARY RADIATION-THERAPY ON DELIVERED DOSE OF ADJUVANT CYCLOPHOSPHAMIDE, METHOTREXATE, AND 5-FLUOROURACIL (CMF) CHEMOTHERAPY IN BREAST-CANCER
    LEVINE, JF
    COLEMAN, CN
    COX, RS
    RAY, GR
    ROGOWAY, WM
    MARTINEZ, A
    STOCKDALE, FE
    CANCER, 1984, 53 (02) : 237 - 241
  • [33] ADJUVANT CHEMOTHERAPY OF BREAST CANCERS BY AN ASSOCIATION OF CYCLOPHOSPHAMIDE, VINCRISTINE, METHOTREXATE AND FLUOROURACIL
    SWIERCZ, P
    SCHAERER, R
    MOUSSEAU, M
    GABELLE, P
    KOLODIE, H
    VINCENT, F
    BOLLA, M
    BULLETIN DU CANCER, 1982, 69 (04) : 368 - 368
  • [34] High dose epirubicin and cyclophosphamide (EC) vs cyclophosphamide, methotrexate, fluorouracil (CMF) as adjuvant chemotherapy in high risk premenopausal breast cancer patients (PTS). A prospective randomized trial
    Galligioni, E
    Cetto, G
    Nascimben, O
    Buonadaona, A
    Crivellari, D
    Molino, A
    Veronesi, A
    Graiff, C
    Barni, S
    Puccetti, C
    Ferrazzi, E
    Recaldin, E
    Sava, C
    Saracchini, S
    Sacco, C
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S36 - S36
  • [35] ON THE SAFETY OF PERIOPERATIVE ADJUVANT CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, METHOTREXATE AND 5-FLUOROURACIL IN BREAST-CANCER
    RUDENSTAM, CM
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (08): : 1305 - 1308
  • [36] Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (cmf regimen)
    Locatelli, M
    Colleoni, M
    Noberasco, C
    Nolé, F
    Orlando, L
    Munzone, E
    Peruzzotti, G
    Goldhirsch, A
    ANNALS OF ONCOLOGY, 1999, 10 (11) : 1394 - 1395
  • [37] A CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH MELPHALAN VERSUS CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL FOR BREAST-CANCER
    HOWELL, A
    RUBENS, RD
    BUSH, H
    GEORGE, WD
    HOWAT, JMT
    CROWTHER, D
    SELLWOOD, RA
    HAYWARD, JL
    KNIGHT, RK
    BULBROOK, RD
    FENTIMAN, IS
    CHAUDARY, M
    RECENT RESULTS IN CANCER RESEARCH, 1984, 96 : 74 - 89
  • [38] ADJUVANT CHEMOTHERAPY WITH ADRIAMYCIN, FLUOROURACIL, CYCLOPHOSPHAMIDE, METHOTREXATE, WITH OR WITHOUT TAMOXIFEN IN OPERABLE BREAST-CANCER
    LLUCHHERNANDEZ, A
    CERVANTESRUINEREZ, A
    ANTONTORRES, A
    AVINOVIGUER, J
    MARTINEZAGULLO, A
    MENGUALCOLOMER, F
    CIUDADPLATERO, J
    ALBEROLACANDEL, V
    GARCIACONDE, J
    TUMORI, 1987, 73 (05) : 467 - 473
  • [39] CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FLUOROURACIL (CMF) IN ADVANCED GASTRO-INTESTINAL CANCER
    SCANNI, A
    TOMIROTTI, M
    MARGULIS, A
    BIRAGHI, M
    CURTARELLI, G
    TUMORI, 1979, 65 (01) : 111 - 117
  • [40] Tolerability and safety of classic cyclophosphamide, methotrexate, and fluorouracil treatment in Japanese patients with early breast cancer.
    Tada K.
    Ito Y.
    Takahashi S.
    Iijima K.
    Miyagi Y.
    Nishimura S.
    Takahashi K.
    Makita M.
    Iwase T.
    Yoshimoto M.
    Kasumi F.
    Breast Cancer, 2006, 13 (3) : 279 - 283
12345